product name Calcifediol
Description: Calcifediol (also known as 25-hydroxyvitamin D3) is a major circulating metabolite of vitamin D3 and acts as a competitive inhibitor with an apparent Ki of 3.9 μM. It also suppresses PTH secretion and mRNA (ED50=2 nM). Calcifediol induced CYP24A1 expression with EC50 at 70 nM. Calcifediol stimulated the expression of thrombomodulin with EC50 at 10-100 nM. Confocal microscopy revealed that calcifediol at 0.1 – 10 μM induced VDR translocation into the nucleus dose-dependently; the VDR localization pattern was similar in cells treated with calcitriol.
References: Cardiovasc Drugs Ther. 2011 Jun;25(3):215-22; Hypertension. 1994 Aug;24(2):176-82.
400.64
Formula
C27H44O2
CAS No.
19356-17-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 80 mg/mL (199.7 mM)
Water: <1 mg/mL
Ethanol: 20 mg/mL (49.9 mM)
Solubility (In vivo)
2% DMSO+30% PEG 300+5% Tween+ddH2O: 5mg/mL
Synonyms
25-hydroxyvitamin D3
other peoduct :
| In Vitro |
In vitro activity: Calcifediol induced CYP24A1 expression with EC50 at 70 nM. Calcifediol stimulated the expression of thrombomodulin with EC50 at 10-100 nM. Confocal microscopy revealed that calcifediol at 0.1 – 10 μM induced VDR translocation into the nucleus dose-dependently; the VDR localization pattern was similar in cells treated with calcitriol. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Spontaneously hypertensive rats and normotensive Wistar-Kyoto (WKY) rats were injected with either 50 ng/d calcifediol or vehicle alone for 3 days. Decreased calbindin-D9K and cellular Ca2+ flux were observed in control SHR. Calcifediol increased total cell and brush border calbindin-D9K. In contrast, Ca2+ flux, which increased in vit-D animals, remained lower in SHR for plasma calcitriol levels similar to those in WKY rats. |
| Animal model | |
| Formulation & Dosage | |
| References | Cardiovasc Drugs Ther. 2011 Jun;25(3):215-22; Hypertension. 1994 Aug;24(2):176-82. |
